Background {#Sec1}
==========

Hypoxia inducible factor 1 (HIF1) is a transcription factor that coordinates the response to hypoxia in cells and tissues \[[@CR1]\]. HIF1 is a heterodimeric protein consisting of HIF1A and HIF1B subunits. The HIF1A subunit is induced by hypoxia and forms an active transcription inducer with HIF1B \[[@CR2]\]. *HIF1* activation promotes the expression of several hypoxia-adaptation genes, including those involved in the biological processes of angiogenesis, erythropoiesis, cell proliferation, and apoptosis \[[@CR3], [@CR4]\].

Hypoxia is a common issue in tumor tissues \[[@CR5]\]. HIF1A regulates cellular adaptation to hypoxia and promotes tumor development \[[@CR6]--[@CR8]\]. HIF1A expression increases in various types of cancer, such as breast, prostate, and colon cancer \[[@CR9]\], and a high expression of HIF1A in a tumor indicates poor patient prognosis \[[@CR10]\]. The relapse-free survival time is significantly lower for the hepatocellular carcinoma patients with high expression of HIF1A than for patients with low expression \[[@CR11]\].

The rs2057482 polymorphism is located in the 3′ untranslated region (3′-UTR) region of the *HIF1A* gene. The SNP has been widely explored for its relationship with cancer risk \[[@CR12]--[@CR18]\]. We performed this meta-analysis to provide a more accurate assessment and obtain a comprehensive understanding of the relationship between rs2057482 and cancer risk.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Three databases (PubMed, Embase, and Web of Science) were retrieved up to September 24, 2019, using the following keywords: "*hypoxia inducible factor 1 subunit alpha* or *HIF1A*," "polymorphism or variant or mutation or SNP," and "cancer or carcinoma or tumor." We also checked the Ensembl web site for potential studies (<http://asia.ensembl.org/Homo_sapiens/Variation>).

Inclusion and exclusion criteria {#Sec4}
--------------------------------

The inclusion criteria were: The study is about the relationship between rs2057482 and cancer risk.The study is a case-control study or cohort study.The study must contain sufficient genotype data for the meta-analysis.The study is published in English.

We excluded reviews, meta-analyses, and abstracts.

Data extraction {#Sec5}
---------------

The data from the selected studies were extracted by two authors separately. The extracted data were the following: first author; publication year; country or region where the study conducted; control source; genotype methods; and genotype frequencies.

Quality score {#Sec6}
-------------

We evaluated the quality of these included studies by scoring each study based on the case and control source, number of subjects, and Hardy-Weinberg equilibrium (Additional file [1](#MOESM1){ref-type="media"}: Table S1) \[[@CR19]\].

Statistical analysis {#Sec7}
--------------------

Statistical analyses were carried out using the Stata software (Version 12.0, Stata Corporation, College Station, TX). ORs and 95%Cls were calculated to evaluate the strength of the association between the rs2057482 polymorphism and cancer risk. *P* values \< 0.05 were considered statistically significant. This meta-analysis used five genetic models: the allele (T vs. C), homozygote (TT vs. CC), heterozygote (CT vs. CC), dominant (TT + CT vs. CC), and recessive models (TT vs. CT + CC). We also conducted stratified analysis of ethnicity; however, only one study was about the Caucasian population, so we have only shown results for the Asian population. In addition, only one study was retrieved about each type of cancer, so we did not conduct a stratified analysis of cancer type. We measured the heterogeneity with the parameter I^2^ and the *P*-value with the Chi-squared test \[[@CR20]\]. When I^2^ \< 50% or *P* \> 0.10, the fixed model was used \[[@CR21]\]; otherwise, a random model was used \[[@CR22]\]. Sensitivity analyses were performed by removing one study each time \[[@CR23]\]. Publication bias was determined using the Egger and Begg tests \[[@CR24], [@CR25]\].

Results {#Sec8}
=======

Characteristics of the studies {#Sec9}
------------------------------

The process used to select target articles is shown in Fig. [1](#Fig1){ref-type="fig"}. The database searches identified 949 studies after removing duplicate records. A further check of the titles and abstracts excluded 915 studies. We read the full text of the remaining 34 studies and ultimately selected 7 studies for the meta-analysis. The included studies were conducted between 2008 and 2018; five studies were about the Asian population, one was about the Caucasian population, and one was about a mixed population. The characteristics of these studies are shown in Table [1](#Tab1){ref-type="table"}. The genotype frequencies are listed in Table [2](#Tab2){ref-type="table"}. Fig. 1The flow diagram of included/excluded studies Table 1Characteristics of the studies included in the meta-analysisFirst authorYearCountry/\
RegionEthnicityCancer typeGenotyping\
methodControl sourceLee (12)2008KoreaAsianbreast cancerSNP-IT™ assaysPBQin (13)2011ChinaAsianRCCTaqmanHBLi (14)2012ChinaAsianprostate cancerTaqmanHBWang (15)2016ChinaAsianPDACDNA sequencePBYamamoto (16)2016JapanAsianlung cancerTaqmanHBGregory (17)2016USAMixNHLFluidigm Dynamic 96.96 Array™ assayHBMartina (18)2018CzechCaucasianMMTaqmanHBRCC, renal cell carcinoma; PDAC, pancreatic ductal adenocarcinoma; NHL: non-Hodgkin lymphoma; MM: multiple myeloma; PB, population-based; HB, hospital-based Table 2*HIF1A* rs2057482 polymorphism genotype distribution and allele frequency in cases and controlsGenotype(N)Allele frequency (N)HWEScoreCaseControlCaseControlTotalCCCTTTTotalCCCTTTCTCTLee 2008 (12)115069141544104861139641179750316184780.01811Qin 2011 (13)62038819636623393201299722689872590.61312Li 2012 (14)6624182123271642824147104827610973350.10312Wang 2016 (15)4103016940490302154346711497582220.02210Yamamoto 2016 (16)46230213822379244121147421826091490.83411Gregory 2016 (17)18012549652836914712299618851710.55411Martina 2018 (18)27522547321917639449753391470.29710HWE: Hardy-Weinberg equilibrium

Meta-analysis {#Sec10}
-------------

In this meta-analysis, the overall analysis under the dominant genetic model showed a significant association between the rs2057482 polymorphism and a decreased risk of cancer (Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}, TT + CT vs. CC: OR, 0.89, 95% CI, 0.81--0.98, *P* = 0.017). However, the stratified analysis of ethnicity did not indicate an association between rs2057482 and cancer risk in the Asian population in any of the genetic models (Table [3](#Tab3){ref-type="table"}). We only synthesized the results if two or more studies were available, so the results for the Caucasian population were not shown. Table 3Meta-analysis of the association between rs2057482 polymorphism and cancer susceptibilitySubgroupNo.T vs. CTT vs. CCCT vs. CCTT + CT vs. CCTT vs. CT + CCOR(95%Cl)*P*~*OR*~I^2^OR(95%Cl)*P*~*OR*~I^2^OR(95%Cl)*P*~*OR*~I^2^OR(95%Cl)*P*~*OR*~I^2^OR(95%Cl)*P*~*OR*~I^2^Overall70.93(0.86--1.01)0.0814.4%1.01(0.82--1.26)0.9030.0%0.85(0.71--1.03)^\*^0.09166.8%**0.89(0.81--0.98)0.017**45.6%1.08(0.87--1.33)0.5023.6%Asian50.93(0.85--1.01)0.07028.8%1.01(0.81--1.26)0.9430.2%0.82(0.65--1.04)^\*^0.09677.2%0.87(0.73--1.03)^\*^0.09561.8%1.08(0.86--1.34)0.52623.4%OR*,* odds ratio; 95% CI, 95% confidence interval; *P*~*OR*~, pool *P* value; RCC, renal cell carcinoma; **\***indicates that the OR, 95% Cl, and corresponding *P*~*OR*~ were calculated based on the random-effects model; otherwise, the fixed-effects model was used. Bold values are statistically significant (P~OR~ \< 0.05) Fig. 2Meta-analysis of the association between rs2057482 and risk of cancer **a**: allele model; **b**: homozygous model; **c**: heterozygous model; D: dominant model; E: recessive model**.** The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary OR and 95% CI. The random-effects model was used for the heterozygous genetic model, and fixed-effects models were used for other genetic models.

Sensitivity analysis {#Sec11}
--------------------

Sensitivity analyses were performed using the *metainf* command. Exclusion of the Qin2011 study led to a different result in the allele model, and exclusion of the Wang2016 study led to a different result in the dominant model (Fig. [3](#Fig3){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2). We also preformed sensitivity analyses in Asian populations. Exclusion of the Qin2011 study led to a different result in the allele model (Additional file [1](#MOESM1){ref-type="media"}: Table S3). These results suggest that our results were not stable in these models. Fig. 3Sensitivity analyses between rs2057482 polymorphism and risk of cancer **a**: allele model; **b**: homozygous model; **c**: heterozygous model; **d**: dominant model; **e**: recessive model**.** The random-effects model was used for the heterozygous genetic model, and fixed-effects models were used for other genetic models.

Publication bias {#Sec12}
----------------

Egger and Begg tests carried out to detect potential publication bias revealed no publication bias in this meta-analysis (Table [4](#Tab4){ref-type="table"}). Table 4Publication bias analysisGenetic modelEgger's testBegg's testt95% Cl*PP*T vs. C−0.03−3.644\~3.5730.9811.000TT vs. CC0.23−2.671\~3.2070.8240.764CT vs. CC−0.60−7.483\~4.6600.5760.548TT + CT vs. CC−0.28−5.559\~4.4700.7910.764TT vs. CT + CC0.09−3.138\~3.3710.9301.000

Discussion {#Sec13}
==========

HIF1A plays a central role in tumor adaptation to hypoxia \[[@CR26], [@CR27]\]. HIF1A mediates the hypoxic adaptation of tumor cells and tissues in multiple ways \[[@CR28]\]. For example, angiogenesis is an important aspect of cancer progression, and HIF1A contributes to tumor angiogenesis by upregulating vascular endothelial growth factor (VEGF) and other proangiogenic factors \[[@CR29], [@CR30]\]. HIF1A also increases the expression of multiple enzymes involved in glycolysis, which further aids tumor cell growth and proliferation \[[@CR31]--[@CR34]\]. In addition, HIF1A promotes autophagy by altering the expression of BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3), which is part of a stress adaptation mechanism that promotes tumor cell survival and avoids cell death \[[@CR35], [@CR36]\]. Many studies have reported associations between *HIF1A* polymorphisms and the risks of various types of cancer, including bladder, oral, and colorectal cancers, head and neck squamous cell carcinoma, and renal cell carcinoma \[[@CR37]--[@CR40]\].

The *HIF1A* gene has many SNPs, but we focused on rs2057482 for the following reasons: First, the relationship between rs2057482 and cancer risk has been reported in previous epidemiology studies \[[@CR12]--[@CR18]\]. Second, in the 1000 Genomes Project Phase 3, minor allele frequencies of rs2057482 are greater than 10% in most populations (Additional file [1](#MOESM1){ref-type="media"}: Table S4). Third, the selected SNP may have important biological functions, according to previous reports.

The rs2057482 polymorphism is located in the 3'UTR of *HIF1A*. Many researchers have hypothesized that this polymorphism may be located near the microRNA binding site and that it affects the expression of HIF1A by binding HIF1A to the microRNA \[[@CR13], [@CR15]--[@CR18]\]. Wang et al. reported that rs2057482 may affect the expression of HIF1A by microRNA 199a \[[@CR15]\]. Gregory et al., based on silico analyses with the miRNA-SNP analytic tool TargetScan 5.2, suggested that the T allele of *HIF1A* rs2057482 created new microRNA binding sites for microRNA 196a-2 \[[@CR17]\].

The rs2057482 polymorphism has been reported to associate with the occurrence and prognosis of several kinds of cancer \[[@CR41]--[@CR44]\]. For example, this polymorphism was found to decrease the risk of non-Hodgkin's lymphoma associated with central nervous system acquired immune deficiency syndrome \[[@CR17]\]. An association has also been reported between rs2057482 polymorphism and prognosis of early-stage lung cancer patients after surgery \[[@CR45]\]. In addition, the recurrence rate of hepatocellular carcinoma is lower in CT + TT carrier patients than in CC carrier patients \[[@CR11]\].

Our meta-analysis revealed that rs2057482 decreased the overall cancer risk in the dominant genetic model. We hypothesize that the carrier of the T allele (CT + TT) creates a new microRNA binding site. Binding leads to decreased expression of HIF1A, thereby reducing the risk of cancer. However, this conclusion is made based on only seven types of tumor (breast, lung, prostate cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, non-Hodgkin's lymphoma, and multiple myeloma); therefore, we suggest that the relationship between rs2057482 and more types of cancer should be investigated in further studies.

The current meta-analysis has the following limitations that should be recognized. First, the number of studies contained in the meta-analysis is limited, and the majority of the study populations were Asians. The genomic effect of this SNP could be ethnicity specific, so this prevalence of Asian subjects may have biased the results for overall cancer risk. The present study results therefore only provide meaningful information for Asian populations, and we recommend additional research on the risk of cancer and rs2057482 in Caucasian and other populations in the future. Second, only one study was included for each cancer type, so we did not conduct a stratified analysis based on cancer type. Each type of cancer may have a different underlying genomic mechanism, so more studies on rs2057482 and cancer risk are needed for each type of cancer. Finally, the mechanism by which this SNP affects tumor risk is still unclear and needs further exploration.

Conclusions {#Sec14}
===========

Our meta-analysis suggests that the rs205782 polymorphism of the *HIF1A* gene significantly decreases the overall cancer risk, based on the synthesis results of the included studies. This conclusion should be further verified by additional studies that include more subjects and cancer types.
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**Additional file 1: Table S1.** Quality score assessment. **Table S2.** Sensitivity analyses for rs2057482 polymorphism and cancer susceptibility. **Table S3.** Sensitivity analyses for rs2057482 polymorphism and cancer susceptibility in Asian population. **Table S4.** MAFs of rs2057482 polymorphism in the populations from the 1000 Genomes Project Phase 3.
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